Suter-Dick, Laura

Profilbild
E-Mail-Adresse
Geburtsdatum
Projekt
Organisationseinheiten
Berufsbeschreibung
Nachname
Suter-Dick
Vorname
Laura
Name
Suter-Dick, Laura

Filter

20212
Filter zurücksetzen

Einstellungen

Autor:in: Lanz, Henriette × Item-Typ: Publikation × Dateien dazu vorhanden?: Ja ×

Suchergebnisse

Gerade angezeigt 1 - 2 von 2
  • Vorschaubild
    Publikation
    Implementation of a human renal proximal tubule on a chip for nephrotoxicity and drug interaction studies
    (Elsevier, 04.04.2021) Suter-Dick, Laura; Caj, Michaela; Hutter, Simon; Vormann, Marianne; Vriend, Jelle; Lanz, Henriette; Gijzen, Linda; van den Heuvel, Angelique; Joore, Jos; Trietsch, Sebastian; Stuut, Christaan; Nieskens, Tom T.G.; Peters, Janny; Ramp, Daniela; Russel, Frans; Roth, Adrian; Lu, Shuyan; Polli, Joseph; Jacobsen, Björn [in: Journal of Pharmaceutical Sciences]
    Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI). Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI, probably due to the lack of physiological architecture and flow. Here, we assessed a high throughput, 3D microfluidic platform (Nephroscreen) for the detection of DIKI in pharmaceutical development. This system was established with four model nephrotoxic drugs (cisplatin, tenofovir, tobramycin and cyclosporin A) and tested with eight pharmaceutical compounds. Measured parameters included cell viability, release of lactate dehydrogenase (LDH) and N-acetyl-β-d-glucosaminidase (NAG), barrier integrity, release of specific miRNAs, and gene expression of toxicity markers. Drug-transporter interactions for P-gp and MRP2/4 were also determined. The most predictive read outs for DIKI were a combination of cell viability, LDH and miRNA release. In conclusion, Nephroscreen detected DIKI in a robust manner, is compatible with automated pipetting, proved to be amenable to long-term experiments, and was easily transferred between laboratories. This proof-of-concept-study demonstrated the usability and reproducibility of Nephroscreen for the detection of DIKI and drug-transporter interactions. Nephroscreen it represents a valuable tool towards replacing animal testing and supporting the 3Rs (Reduce, Refine and Replace animal experimentation).
    01A - Beitrag in wissenschaftlicher Zeitschrift
  • Vorschaubild
    Publikation
    Nephroscreen. A robust and versatile renal tubule-on-a-chip platform for nephrotoxicity assessment
    (Elsevier, 03/2021) Suter-Dick, Laura; Vriend, Jelle; Vormann, Marianne; Lanz, Henriette; Joore, Jos; Trietsch, Sebastian J.; Russel, Frans; Jacobsen, Björn; Roth, Adrian; Lu, Shuyan; Polli, Joseph; Naidoo, Anita; Masereeuw, Rosalinde; Wilmer, Martijn [in: Current Opinion in Toxicology]
    Proximal tubule epithelial cells are the main driver of renal transport and secretion of xenobiotics, making them susceptible to drug-induced kidney injury. Cell-based assays are a meaningful alternative to animal testing to detect nephrotoxicity and contribute to the 3Rs (refine, reduce, replace animal experimentation). Here we report on a high-throughput, three-dimensional microfluidic platform (Nephroscreen) to detect drug-induced nephrotoxicity. Toxicologically relevant parameters were used to assess cell viability, functional epithelial barrier integrity, and interactions with specific transporters (P-glycoprotein: P-gp and multidrug resistance–associated protein 2/4: MRP2/4). Nephroscreen allowed the combination of a variety of read-outs, including imaging, extracellularly released markers, intracellular markers, and functional assays. Nephroscreen is compatible with automated pipetting, proved to be amenable to long-term experiments (at least 11 days), and was easily transferred between laboratories. The compelling data originate from several published reports on the development and implementation of this platform to detect nephrotoxicity and drug–transporter interactions. The reports demonstrate that Nephroscreen could be used to detect the nephrotoxic liabilities of the tested compounds. Future directions should include additional test compounds and thorough validation of its performance.
    01A - Beitrag in wissenschaftlicher Zeitschrift